Compare AUPH & BBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUPH | BBT |
|---|---|---|
| Founded | 1993 | 1846 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2014 | 2000 |
| Metric | AUPH | BBT |
|---|---|---|
| Price | $16.96 | $30.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.25 | ★ $33.25 |
| AVG Volume (30 Days) | ★ 858.1K | 632.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 4.12% |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | 0.53 | ★ 1.32 |
| Revenue | $283,055,000.00 | ★ $400,000,000.00 |
| Revenue This Year | $17.54 | $77.88 |
| Revenue Next Year | $15.74 | $4.31 |
| P/E Ratio | $32.00 | ★ $23.47 |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $10.34 | $22.81 |
| 52 Week High | $19.25 | $32.83 |
| Indicator | AUPH | BBT |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 42.07 |
| Support Level | $15.65 | $30.30 |
| Resistance Level | $17.80 | $31.89 |
| Average True Range (ATR) | 0.42 | 0.65 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 85.50 | 26.16 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.